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Objective: To evaluate the performance of the Decipher test in predicting lymph node invasion 
(LNI) on radical prostatectomy (RP) specimens.
Methods: We identified 1,987 consecutive patients with RP who received the Decipher test 
between February and August 2015 (contemporary cohort). In the contemporary cohort, only 
the Decipher score from RP specimens was available for analysis. In addition, we identified 
a consecutive cohort of patients treated with RP between 2006 and 2012 at the University of 
California, San Diego, with LNI upon pathologic examination (retrospective cohort). The 
retrospective cohort yielded seven, 22, and 18 tissue specimens from prostate biopsy, RP, and 
lymph nodes (LNs) for individual patients, respectively. Univariable and multivariable logistic 
regression analyses were used to evaluate the performance of Decipher in the contemporary 
cohort with LNI as the endpoint. In the retrospective cohort, concordance of risk groups was 
assessed using validated cut-points for low (,0.45), intermediate (0.45–0.60), and high (.0.60) 
Decipher scores.
Results: In the contemporary cohort, 51 (2.6%) patients had LNI. Decipher had an odds ratio 
of 1.73 (95% confidence interval, 1.46–2.05) and 1.42 (95% confidence interval, 1.19–1.7) per 
10% increase in score on univariable and multivariable (adjusting for pathologic Gleason score, 
extraprostatic extension, and seminal vesicle invasion), respectively. No significant difference in 
the clinical and pathologic characteristics between the LN positive patients of contemporary and 
retrospective cohorts was observed (all P.0.05). Accordingly, among LN-positive patients in the 
contemporary cohort and retrospective cohort, 80% and 77% had Decipher high risk scores (P=1). 
In the retrospective cohort, prostate biopsy cores with the highest Gleason grade and percentage 
of tumor involvement had 86% Decipher risk concordance with both RP and LN specimens.
Conclusion: Decipher scores were highly concordant between pre- and post-surgical specimens. 
Further, Decipher scores from RP tissue were predictive of LNI at RP. If validated in a larger 
cohort of prostate biopsy specimens for prediction of adverse pathology at RP, Decipher may 
be useful for improved pre-operative staging.
Keywords: prostate, biopsy, lymph node invasion, genomic classifier, radical prostatectomy, 
decipher, prognosis
Introduction
Recently, development of genomic signatures in prostate cancer has improved our 
understanding of disease biology.1,2 Decipher® represents one such test that was developed 
to predict disease progression after radical prostatectomy (RP) in a cohort of 359 patients.3 
Since its conception, Decipher has been validated in multiple cohorts with varying 
 levels of risk and patient populations.4–13 In a majority of previous studies, Decipher was 
 performed using formalin-fixed paraffin embedded specimens from whole gland pathol-
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ogy.4–13 Only recently, performance and feasibility of Decipher 
on prostate biopsy (PBx) specimens have been studied.10 In 
the present study, we set to: 1) determine the agreement of 
Decipher among matched PBx, RP, and lymph node (LN) 
pathologic specimens from individual patients and 2) evaluate 
the performance of the Decipher genomic classifier in predict-
ing lymph node invasion (LNI) on RP specimens.
Materials and methods
Patient cohorts
We identified 1,987 consecutive patients with RP who 
received the Decipher test between February 1 and August 
1, 2015, from 308 centers. This contemporary cohort was 
deidentified, and study researchers were blinded to patient 
identities and had no access to personally identifiable health 
information (ClinicalTrials.gov number, NCT02609269). 
The Qurorum Institutional Review Board (record number: 
31079) approved the research protocol for this study. Since 
all patient related data was de-identified and study research-
ers were blinded to patient identities and did not have access 
to personally identifiable health information, it was exempt 
from human subjects review, and members of the study 
population did not have to provide informed consent. In 
the contemporary cohort, only the Decipher score from RP 
specimens was available for analysis.
The retrospective cohort consisted of 25 consecutive 
patients treated with RP between 2006 and 2012 with patho-
logically determined LN metastases (LNI) and available tissue 
blocks and clinical data at the University of California, San 
Diego. For each patient, three PBx cores from their diagnostic 
PBx with tumor tissue were selected based on availability of 
sufficient tissue for genomic analysis. Likewise, RP and LN 
specimens positive for tumor were retrieved. For 16 patients, 
a matched diagnostic PBx core specimen was not available. 
After filtering for specimens that failed microarray quality 
control, retrospective cohort yielded seven, 22, and 18 tissue 
specimens from PBx, RP, and LNs for individual patients, 
respectively. All specimens were rereviewed by an expert 
uropathologist (A.S). The index tumor was considered as the 
lesion with the highest Gleason score sampled using a 1.5 
mm punch tool. The “index” PBx was defined as the core 
with the highest Gleason score and highest percentage of 
tumor involvement. The University of California, San Diego, 
institutional review board approved the research protocol 
under which this study was conducted.
Calculation of Decipher
The expression values for the 22 prespecified biomarkers that 
constitute Decipher were extracted from the normalized data 
matrix and entered into the locked random forest algorithm 
with tuning and weighting parameters defined previously.3 
The Decipher readout is a continuous risk score between 
0 and 1, with higher scores indicating a greater probability 
of disease progression or metastasis.3,7,10 Decipher was also 
stratified into low (,0.45), intermediate (0.45–0.60), and 
high (.0.60) risk groups based on previously developed and 
validated cut-points.9,14
Statistical analysis
Univariable and multivariable (MVA) logistic regression 
analyses were used to evaluate the performance of Decipher 
in predicting LNI in the contemporary cohort. The c-index 
of the pathologic and Decipher plus pathologic models was 
estimated by subjecting the model to bootstrapping with 
10,000 resamples. Fisher’s exact test was used to study the 
association of clinicopathologic variables between study 
cohorts. Exact binomial confidence intervals (CIs) were 
constructed to measure the concordance of Decipher score 
among matched PBx, RP, and LN pathologic specimens in 
the retrospective cohort. Pairwise agreement of Decipher 
scores in the retrospective cohort was evaluated using Bland–
Altman plots.15 All statistical tests involving biopsy samples 
were performed after index PBx sample selection unless 
stated otherwise. In the retrospective cohort, Kaplan–Meier 
method was used to estimate two endpoints: 1) biochemi-
cal recurrence rate, which was defined as a postoperative 
prostate-specific antigen (PSA) value .0.2 on two consecu-
tive measurements; and 2) clinical recurrence rate, which 
was defined as local, and/or distant recurrence defined by 
imaging, and/or prostate-bed biopsy. Statistical analyses 
were performed using the R statistical software (R Founda-
tion for Statistical Computing, Vienna, Austria) considering 
a statistical significance at P,0.05.
Results
Patient characteristics
The clinical and pathologic characteristics of patients tested 
with Decipher in the contemporary cohort are summarized 
in Table 1. Median age at surgery was 67 years (inter-
quartile range [IQR], 61–71). Median pre-operative PSA 
was 6.4 ng/mL (IQR: 4.7–9.6). Overall, 75.5%, 11.1%, and 
13.3% of patients had pathologic Gleason score #7, 8, and 
$9, respectively; 58.9% of patients harbored pT3 disease; 
and 55.4% had positive surgical margins. Fifty-one (2.6%) 
patients presented with LNI at RP.
In the retrospective cohort, 22 patients had complete clini-
cal and pathologic characteristics and Decipher RP scores for 
analysis. A subset of 7 and 18 patients had tissue available 
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from PBx and LN specimens, respectively. Retrospective 
cohort patients’ clinical and pathologic characteristics are 
summarized in Table 2. Median age at surgery was 60 
years (IQR, 57–66). Median pre-operative PSA value was 
6.9 ng/mL (IQR, 4.8–16.1). At biopsy, 91% had Gleason 
score 8–10, 41% had clinical stage T2b disease, and 90.9% 
were classified as high risk by National Comprehensive 
Cancer Network (NCCN) criteria. At RP, 90.9% of patients 
had Gleason score 8–10, 81.9% harbored pT3 disease, and 
54.5% had positive surgical margins. The median follow-up 
time for this cohort was 16 months (IQR, 4–35). At 5 years 
post-RP, the estimated biochemical recurrence rate and 
clinical recurrence rate were 73% and 24%, respectively 
(Figure S1). A comparison of the clinical and pathologic 
Research and Reports in Urology 2016:8
Table 1 Patient clinical and pathologic characteristics in the 
contemporary cohort
Variables Total (%)
No patients (%) 1,987 (100)
Age, year, median (IQR) 65 (62–69)
Pre-operative PSA (ng/mL), median (IQR) 6.4 (4.7–9.6)
Pathologic Gleason score, n (%)
 #7 1,500 (75.5)
 8 220 (11.1)
 $9 264 (13.3)
 Unknown 3 (0.2)
Pathologic stage, n (%)
 T2 772 (38.9)
 T3a 780 (39.3)
 T3b 390 (19.6)
 T4 14 (0.7)
 Unknown 31 (1.6)
Positive surgical margins, n (%) 1,100 (55.4)
Lymph node invasion, n (%) 51 (2.6)
Abbreviations: IQR, interquartile range; PSA, prostate-specific antigen.
Table 2 Patient clinical and pathologic characteristics in the 
retrospective cohort
Variables Total (%)
No patients (%) 22 (100)
Age, year, median (IQR) 60 (57–66)
Pre-operative PSA (ng/mL), median (IQR) 6.9 (4.8–16.1)
Pathologic Gleason score, n (%)
 #7 2 (9.1)
 8 9 (40.9)
 $9 11 (50.0)
 Unknown 0 (0)
Pathologic stage, n (%)
 T2 3 (13.6)
 T3a 8 (36.4)
 T3b 10 (45.5)
 T4 1 (4.5)
Positive surgical margins, n (%) 12 (54.5)
Lymph node invasion, n (%) 22 (100)
Follow-up time (censored), mo, median (IQR) 16 (4–35)
Abbreviations: IQR, interquartile range; mo, months; PSA, prostate-specific antigen; 
yr, year.
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Figure 1 Bar charts showing frequency of Decipher risk groups in (left) contemporary cohort, (center) Ln+ patients of contemporary cohort, and (right) Ln+ patients of 
retrospective cohort from genomic marker assessment in RP specimens.
Abbreviations: Ln, lymph node; RP, radical prostatectomy.
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characteristics of the LNI patients in the contemporary and 
retrospective cohorts did not show any significant difference 
(all P.0.1) between the two cohorts (Table S1).
Patients were also stratified using Decipher risk groups 
(low, intermediate, and high). In the contemporary cohort, 
9.8%, 9.8%, and 80.4% of LN positive patients were catego-
rized as Decipher low, intermediate, and high risk, respectively 
(Figure 1). In the retrospective cohort, we observed a similar 
distribution with 9.1%, 13.6%, and 77.3% categorized into 
Decipher low, intermediate, and high risk, respectively. There 
was no significant difference with respect to Decipher distribu-
tion of LN positive patients between the two cohorts (P.0.1).
Evaluation of Decipher for LnI prediction 
in the contemporary cohort
On univariable, Decipher had an odds ratio (OR) of 1.73 
(95% CI, 1.46–2.05, P,0.001) per 10% increase in score 
for predicting the presence of LNI (Table 3). Gleason score 
8 disease had an OR of 8.77 (95% CI, 1.18–65.29, P=0.03). 
Extraprostatic extension (EPE) and seminal vesicle inva-
sion (SVI) also were significant predictors of LNI with OR 
Research and Reports in Urology 2016:8
Table 3 Univariable logistic regression analysis of Decipher and 
pathologic variables for prediction of lymph node invasion in the 
contemporary cohort
Variables/endpoint Lymph node invasion
OR (95% CI) P-value
Deciphera 1.73 (1.46–2.05) ,0.001
Pathologic Gleason score 3+3 ref 1
Pathologic Gleason score 3+4 0.78 (0.08–7.58) 0.83
Pathologic Gleason score 4+3 2 (0.24–16.78) 0.52
Pathologic Gleason score 8 8.77 (1.18–65.29) 0.03
Pathologic Gleason score $9 6.01 (0.79–45.89) 0.08
Extraprostatic extension 6.1 (2.59–14.35) ,0.001
Seminal vesicle invasion 5.74 (3.25–10.13) ,0.001
Note: aDecipher reported per 0.1 unit increase. A statistical significance at P,0.05 
was applied.
Abbreviations: CI, confidence interval; OR, odds ratio; ref, reference group.
4
PBx1
TP 60%, GG 3
TP 90%, GG 5
TP 75%, GG 4
TP 50%, GG 4
TP 10%, GG 4
TP 50%, GG 5
TP 80%, GG 3 TP 60%, GG 4
TP 90%, GG 4
TP 80%, GG 4
TP 100%, GG 4
TP 60%, GG 3 TP 50%, GG 4
TP 75%, GG 5
TP 90%, GG 4
TP 50%, GG 5
TP 80%, GG 4
TP 75%, GG 5 TP 50%, GG 4
TP 100%, GG 4
TP 100%, GG 4
TP 90%, GG 4
TP 5%, GG 4
TP 100%, GG 5
TP 60%, GG 4
TP 90%, GG 4
TP 100%, GG 5TP 80%, GG 5
TP 90%, GG 4
TP 80%, GG 4
TP 100%, GG 4
TP 95%, GG 4
TP 95%, GG 5
TP 80%, GG 4
TP 60%, GG 4
TP 100%, GG 4
TP 100%, GG 4
TP 85%, GG 4
TP 50%, GG 4
TP 30%, GG 4
TP 50%, GG 4
TP 100%, GG 5
TP 70%, GG 5
TP 90%, GG 5
TP 50%, GG 3
TP 100%, GG 4
TP 90%, GG 3
TP 100%, GG 5
TP 5%, GG 3
TP 50%, GG 3
TP 100%, GG 5
TP 75%, GG 5
TP 100%, GG 4
TP 90%, GG 4
TP 20%, GG 4
TP 100%, GG 4
TP 50%, GG 4
PBx2 PBx3
Tumor type
RP LN
26
19
14
3
20
5
7
2
17
22
6
P
at
ie
n
t 
ID
21
16
13
10
24
18
1
23
8
9
Decipher risk Low (<0.45) Intermediate (0.45–0.60) High (>0.60) Unknown
Figure 2 Heat map of Decipher risk groups for all patients in the retrospective cohort.
Abbreviations: GG, highest Gleason grade; Ln, lymph node; PBx, prostate biopsy; RP, radical prostatectomy; TP, tumor percentage.
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of 6.10 (95% CI, 2.59–14.35, P,0.001) and 5.74 (95% CI, 
3.25–10.13, P,0.001), respectively. Patient age at RP and 
pre-operative PSA were not significant predictors of LNI 
(data not shown). Patient age at RP and pre-operative PSA 
were not modeled on MVA as these variables were missing 
for a significant portion of patients.
On MVA, adjusting for pathologic Gleason score, EPE, 
and SVI Decipher had an OR of 1.42 (95% CI, 1.19–1.7, 
P,0.001) per 10% increase in score for predicting the 
presence of LNI (Table 4). EPE and SVI also remained 
significant predictors of LNI on MVA. In contrast, Gleason 
score 8 disease did not remain significant for predicting LNI 
after adjusting for Decipher and other pathologic variables. 
Similar results were observed in univariable and MVA for 
Decipher risk groups (Tables S2 and S3). On MVA analysis 
adjusting for pathologic Gleason score, EPE, and SVI, the 
Decipher high risk group (.0.6) had an OR of 3.23 (95% 
CI, 1.2–8.73, P=0.02), similar to the OR of EPE and SVI 
for predicting the presence of LNI. Finally, discrimination 
analysis showed that Decipher had a c-index of 0.78 (95% 
CI, 0.71–0.84) for prediction of LNI. Combination of 
Decipher with pathologic variables increased the c-index to 
0.85 (95% CI, 0.73–0.86) from 0.83 (95% CI, 0.71–0.84) 
for pathologic model alone (Figure S2).
Concordance of Decipher in pre- and 
post-RP tissue specimens in the 
retrospective cohort
A patient-per-patient pairwise agreement among biopsy cores 
(#3 cores for each patient with available Decipher scores), 
RP, and LN specimens is shown in Figure 2. Among all avail-
able PBx specimens, 65% were categorized as Decipher high 
risk, whereas 100% of selected PBx specimens (highest sam-
pled Gleason grade and percentage of tumor involvement), 
77% RP, and 78% LN specimens had high Decipher scores. 
Bland–Altman plots, which examined patient-per-patient 
agreement, showed a good overall concordance for all three 
compared tissue specimens (Figure S3).
Finally, we examined Decipher agreement in pairwise 
comparisons between the following 1) PBx and RP speci-
mens, 2) PBx and LN specimens, and 3) RP and LN speci-
mens when PBx selection was performed (Table 5). Without 
selection of PBx specimens (ie, taking the average Decipher 
score for all cores), the overall concordance with RP Decipher 
risk groups was 71%, which increased to 86% concordance 
when the selected PBx core (ie, with the highest sampled 
Gleason grade and percentage of tumor involvement) was 
compared to RP Decipher. The concordance between PBx 
and LN was 43% for the average of all PBx specimens in 
each patient and similarly increased to 86% when compar-
ing only the PBx with highest sampled Gleason grade and 
percentage of tumor involvement. The concordance of RP 
and LN Decipher scores was 72%.
Discussion
Here, we evaluated the performance of Decipher scores on 
RP specimens for prediction of LNI in a contemporary cohort 
and then in an exploratory analysis of a small retrospective 
cohort determined the agreement of Decipher scores among 
pre- and post-operative tissue specimens, including LN with 
tumor involvement. Our results show that Decipher is a strong 
predictor of LNI in a contemporary cohort of nearly 2,000 
patients. In a retrospective cohort, with similar characteris tics 
to the LNI patients of a contemporary RP cohort, we observed 
high concordance between Decipher scores in PBx and both 
RP and LN specimens of individual patients. The caveat is that 
this is only true when the PBx sampled with highest Gleason 
grade and percentage of tumor involvement is selected.
Our study has several limitations. In the contemporary 
cohort: the lack of information on pre-operative variables, 
extended pelvic lymph node dissection (ePLND) status, and 
Research and Reports in Urology 2016:8
Table 4 Multivariable logistic regression analysis of Decipher and 
pathologic variables for prediction of lymph node invasion in the 
contemporary cohort
Variables/endpoint Lymph node invasion
OR (95% CI) P-value
Deciphera 1.42 (1.19–1.7) ,0.001
Pathologic Gleason score 3+3 ref 1
Pathologic Gleason score 3+4 0.39 (0.04–3.92) 0.43
Pathologic Gleason score 4+3 0.56 (0.06–4.95) 0.6
Pathologic Gleason score 8 1.84 (0.23–14.73) 0.57
Pathologic Gleason score $9 0.85 (0.1–7.09) 0.88
Extraprostatic extension 3.48 (1.44–8.41) 0.01
Seminal vesicle invasion 2.73 (1.47–5.08) ,0.001
Note: aDecipher reported per 0.1 unit increase. A statistical significance at P,0.05 
was applied.
Abbreviations: CI, confidence interval; OR, odds ratio; ref, reference group.
Table 5 Concordance of Decipher scores across tumor types 
using various selection methods for biopsy samples with multiple 
tumors in the retrospective cohort
Pairwise 
comparison
Overall 
concordance
Concordance/PBx 
selected based on highest 
TP and dominant GG
PBx-RP (%) 71 (29–96)a 86 (42–100)
PBx-Ln (%) 43 (10–82)a 86 (42–100)
RP-Ln (%) 72 (47–90) 72 (47–90)
Note: aIn case of a tie, sample with highest tumor percent and dominant Gleason 
grade was selected.
Abbreviations: GG, highest Gleason grade; Ln, lymph node; PBx, prostate biopsy; 
RP, radical prostatectomy; TP, tumor percentage.
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number of LN retrieved for all patients. In the retrospective 
cohort: the small sample size of the matched PBx specimens 
and the lack of a matched set of control patients (ie, without 
LNI) to determine the discrimination performance of the 
genomic marker expression in PBx for predicting LNI. We 
aimed to address these issues in part by considering a large 
contemporary cohort that included both LN negative and 
positive patients in order to show the discrimination of the 
genomic marker for predicting the presence of LNI. However, 
further validation of Decipher on larger PBx cohorts is war-
ranted to confirm the results of the current study.
Conclusion
In summary, in our study, Decipher was highly predictive of LNI 
from analysis of RP specimens in a large contemporary cohort. 
Improved post-operative LNI staging may be useful for selection 
of patients for adjuvant hormonal or whole  pelvic irradiation. 
Decipher scores were also highly concordant between pre- and 
post-operative specimens. If validated in a larger cohort of PBx 
specimens, Decipher may improve pre-operative staging, which 
is useful for optimal selection of patients for neoadjuvant therapy, 
primary radiotherapy as well as RP with ePLND.
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Table S2 Univariable logistic regression analysis of categorical 
Decipher and pathologic variables for prediction of lymph node 
invasion in the contemporary cohort
Variables/endpoint Lymph node invasion
OR (95% CI) P-value
Decipher low risk ref 1
Decipher intermediate risk 1.76 (0.51–6.11) 0.37
Decipher high risk 7.7 (3.03–19.58) ,0.001
Pathologic Gleason score 3+3 ref 1
Pathologic Gleason score 3+4 0.78 (0.08–7.58) 0.83
Pathologic Gleason score 4+3 2 (0.24–16.78) 0.52
Pathologic Gleason score 8 8.77 (1.18–65.29) 0.03
Pathologic Gleason score $9 6.01 (0.79–45.89) 0.08
Extraprostatic extension 6.1 (2.59–14.35) ,0.001
Seminal vesicle invasion 5.74 (3.25–10.13) ,0.001
Abbreviations: CI, confidence interval; OR, odds ratio; ref, reference group.
Note: A statistical significance at P,0.05 was applied.
Table S3 Multivariable logistic regression analysis of categorical 
Decipher and pathologic variables for prediction of lymph node 
invasion in the contemporary cohort
Variables/endpoint Lymph node invasion
OR (95% CI) P-value
Decipher low risk ref 1
Decipher intermediate risk 1.23 (0.35–4.38) 0.75
Decipher high risk 3.23 (1.2–8.73) 0.02
Pathologic Gleason score 3+3 ref 1
Pathologic Gleason score 3+4 0.41 (0.04–4.12) 0.45
Pathologic Gleason score 4+3 0.64 (0.07–5.72) 0.69
Pathologic Gleason score 8 2.46 (0.31–19.57) 0.4
Pathologic Gleason score $9 1.1 (0.13–9.25) 0.93
Extraprostatic extension 3.93 (1.63–9.46) ,0.001
Seminal vesicle invasion 3.09 (1.67–5.73) ,0.001
Abbreviations: CI, confidence interval; OR, odds ratio; ref, reference group.
Note: A statistical significance at P,0.05 was applied.
Table S1 Comparison of LnI patient characteristics from 
retrospective and contemporary cohorts
Variables Retrospective 
cohort N=22
Contemporary 
cohort LN 
N=51
P-value*
Patient characteristics
Age, yr, median (IQR) 60 (57–66) 65 (64–68)
Pre-operative PSA 
(ng/mL), median (IQR)
6.9 (4.8–16.1) 7.58 (5.1–11.8)
Pathologic Gleason  
score, n (%)
.0.1
 #7 2 (9.1) 10 (19.6)
 8 9 (40.9) 25 (49.0)
 $9 11 (50.0) 15 (29.4)
 Unknown 0 (0.0) 1 (2.0)
Pathologic stage, n (%) .0.1
 T2 3 (13.6) 5 (9.8)
 T3a 8 (36.4) 16 (31.4)
 T3b 10 (45.5) 29 (56.9)
 T4 1 (4.5) 1 (2.0)
Note: *Fisher’s exact test. A statistical significance at P,0.05 was applied.
Abbreviations: IQR, interquartile range; Ln, lymph node; LnI, lymph node invasion; 
PSA, prostate-specific antigen; yr, year.
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Figure S3 Pairwise Bland–Altman plots to evaluate agreement of Decipher scores 
between (A) PBx and RP, (B) PBx and Lns, and (C) RP and Lns in retrospective 
cohort.
Abbreviations: PBx, prostate biopsy; RP, radical prostatectomy; Ln, lymph node.
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Figure S2 ROC curves of Decipher and pathologic variables in the contemporary 
cohort.
Abbreviation: CI, confidence interval.
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Figure S1 Kaplan–Meier estimates of survival-free (A) BCR and (B) CR in retrospective cohort.
Abbreviations: BCR, biochemical recurrence; CR, clinical recurrence; RP, radical prostatectomy.
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